Cystic fibrosis
An inherited condition that makes the body produce thick, sticky mucus, which can affect the lungs and the digestive system. Common signs are a lasting cough with mucus, frequent chest infections and, in children, slow growth. There is no cure yet, but medicines, physiotherapy and diet support can help. A child gets it only when both parents pass on the altered gene, and many people diagnosed today are expected to live well past middle age.
Read more about cystic fibrosisTrial-stage treatments and research studies you can joinOpen trials for referral
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Filters
Search the publications
The results open on the publications page in a new tab, so this page stays as it is.
Lists with this disease filtered
Where treatment stands
There is no cure yet, but treatment can often manage the symptoms, and many people diagnosed today will live well past middle age.
Approved: 10
Treatments officially approved for this disease in Luxembourg. An EU approval is valid in Luxembourg. We did not check national approvals there for this disease.
Choose “All countries” for the whole list.
Human testing stage: 4
Being tested in people. Many treatments at this stage are never approved.
Support organisations
Patient organisations and helplines in Luxembourg, for you and your family.
Cystic fibrosis organisations in Luxembourg
- Association Luxembourgeoise de Lutte contre la Mucoviscidose (ALLM)
Luxembourg association on cystic fibrosis (mucoviscidose) with information on the disease, news, an agenda and a donation and membership section.
General support in Luxembourg
- SOS Détresse asbl
Luxembourg non-profit offering free, confidential and anonymous emotional support by phone (454545) and online to people going through hard times.
- Médiateur Santé – Service national d'information et de médiation dans le domaine de la santé
Luxembourg's national service informing patients about their rights and mediating disputes between patients and healthcare providers.
- Patientevertriedung asbl
Patientevertriedung asbl represents patients in Luxembourg and gives practical advice on patients' problems with the health system.
- Portail Santé – Luxembourg
Health portal published by the Luxembourg Ministry of Health for all citizens, with information on health, prevention and the care system.
International organisations
- Cystic Fibrosis Europe
Federation of national CF patient organisations: patient perspective in standards of care, member training and information, patient-driven research (PORG), EU advocacy.
Frontlight Community
Cystic fibrosis community in Luxembourg
People living with cystic fibrosis and those close to them share what they went through. Posts are not medical advice: ask your doctor about your own treatment.
You need a Frontlight account with a verified e-mail address to comment.
Offer tissue or data
There are three ways to help research move faster.
Approved treatments
23 medicines are approved for cystic fibrosis in at least one of the places we checked. An approval in one place does not mean the medicine is offered or paid for where you live.
Checked on 19 Nov 2026 in the official lists of the US (FDA), the EU (European Commission and EMA), Switzerland (Swissmedic) and Canada (Health Canada: its notices of a new or changed use from the last 13 months; for other medicines we checked only whether they are sold there), which we read every day. The lists of Japan (PMDA, approvals since April 2004), France (ANSM, medicines approved in France only) and Taiwan (TFDA) were checked on 11 Nov 2026. For Singapore (HSA) we checked only whether a medicine is sold there, not what for. The French ratings are the opinions of the HAS Transparency Committee, from the French public medicines database (base de données publique des médicaments, newest opinion 10 Dec 2025). 2 uncertain matches are left out. We do not read other countries' own approval registers yet, so we cannot say whether these medicines are approved there.
“Miracle cure” fact checker
Social media spreads misinformation. Paste here what you read, and we'll tell you whether there is scientific evidence behind it.
What you paste is checked with AI (Anthropic, USA) and is not stored. Please leave out names and other personal details.
Before you pay for anything, ask three things
- Is there a published study in people?
- Can I have the full price in writing?
- What does my doctor say?
Donate for research
This function is coming soon as soon as the legal framework is set
Who is researching this now
Research projects that name this disease and have not ended yet, by institution.
No running project led from Luxembourg is known; all countries are shown.
Kobenhavns Universitet
Kobenhavn, Denmark
- Discovery and evolution of CRISPR-Associated Transposons (CAST) for functional RNA-guided integration (CRAFT)until Aug 2029
Universite Paris-Saclay
Gif-Sur-Yvette, France
- Low and very-low-field 3D magnetic resonance spirometry for advanced regional exploration of respiratory diseases (V-LF-Spiro3D)until Mar 2027
Deutsches Elektronen-Synchrotron Desy
Hamburg, Germany
- In vitro and in situ structural characterization of the biofilm-associated functional amyloids in Pseudomonas aeruginosa bacteria (FAPbulous)until Dec 2027
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit und Umwelt Gmbh
Neuherberg, Germany
- CellCourier: programmable drug delivery via combinatorial cell targeting and generative design of tailored binding peptidesuntil Jun 2027
Erevnitiko Kentro Vioiatrikon Epistimon Alexandros Flemingk
Vari-Athens, Greece
- A unified drug discovery platform for protein misfolding diseases (ProMiDis)until Feb 2027
Politecnico di Milano
Milano, Italy
- A doctoral training programme for next-generation LUNG-targeted non-viral GENEtic MEDicines (LUNG-GENEMED)until Nov 2030
Vilniaus Universitetas
Vilnius, Lithuania
- GEM-SEE-Achro: Genomic Exploration—Mapping the Spread, Evolution, and Adaptation of an Emerging bacterial pathogen—Achromobacteruntil Feb 2028
Academisch Ziekenhuis Leiden
Leiden, Netherlands
- Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline (RespiriNTM)until Apr 2027
Universiteit Utrecht
Utrecht, Netherlands
- Organoid technologies for disease modeling, drug discovery and development for rare diseases (ORGESTRA)until Dec 2027
Universidad del Pais Vasco/ Euskal Herriko Unibertsitatea
Leioa, Spain
- Rational Nanoparticle Design for Efficient Transmucosal CRISPR Delivery in Cystic Fibrosis – “CRISPRGels”until Feb 2027
King's College London
London, United Kingdom
- Maternal human milk as a Risk factor to the Early-life Exposome (MATREEX)until Feb 2029
Beth Israel Deaconess Medical Center
Boston, United States
- Elastin-Like Polypeptide Nanoparticles for Precision Gene Therapy of Cystic Fibrosisuntil May 2030
Boston Children's Hospital
Boston, United States
- Shortening the Diagnostic Odyssey for Children with Rare Pulmonary Diseases (RPD)until Jun 2031
Boston University Medical Campus
Boston, United States
- Generation of functional lung stem cells from human iPSCsuntil Jun 2028
College of William and Mary
Williamsburg, United States
- Quorum sensing inhibition as an antibacterial strategy against Pseudomonas aeruginosa infectionsuntil Aug 2029
Colorado State University
Fort Collins, United States
- Bacteriophage interactions with nontuberculous mycobacteria in the intracellular environment of mammalian cellsuntil Aug 2028
Cornell University
Ithaca, United States
- Demographic and evolutionary drivers and consequences of genetic loaduntil Aug 2029
Icahn School of Medicine at Mount Sinai
New York, United States
- Improving VCID outcomes incident to ischemic stroke through mitigation of neutrophil extracellular trapsuntil Aug 2027
Iowa State University
Ames, United States
- Investigating ovotoxic mechanisms of PFASuntil Jun 2031
Mainehealth
Portland, United States
- Targeting MRSA in Cystic Fibrosis: Ceftaroline-Meropenem Combination Therapy and the Predictive Role of PrsAuntil Aug 2028
Max Biopharma, Inc.
Los Angeles, United States
- Examination of anti-fibrotic and immune modulatory effects of Oxy210 for targeting cystic fibrosisuntil Aug 2027
State University of New York at Albany
Albany, United States
- Proteasome-mediated degradation of RhlR controls quorum sensing progression in Pseudomonas aeruginosauntil Sept 2029
University of Chicago
Chicago, United States
- Investigating Early Mycobacterial Interactions with Human Airway Cellsuntil Sept 2028
University of Colorado Denver
Aurora, United States
- Molecular mechanisms of acquired ciliary dysfunction in chronic inflammatory airway diseaseuntil Sept 2029
University of Illinois Chicago
Chapel Hill, United States
- NHLBI MAINTENANCE OF CANINE MODELS OF HUMAN BLEEDING DISORDERSuntil Sept 2027
University of North Texas Hlth Sci Ctr
Fort Worth, United States
- Bioengineering modular gene delivery system towards lung-targeted transgene expressionuntil Aug 2028
University of Notre Dame
Notre Dame, United States
- Intervention of Peptidoglycan Synthesisuntil Aug 2031
University of Pennsylvania
Philadelphia, United States
- Defining the mechanisms of injury resistance and role in restoring mucociliary transport of the airway hillockuntil Aug 2030
University of Puerto Rico Med Sciences
San Juan, United States
- p(UG) RNA Quadruplexes as Nucleators of Stress Granules and Modulators of TDP-43 Pathology in ALSuntil Aug 2030
University of Virginia
Charlottesville, United States
- Importance of type 2 inflammation in cystic fibrosis patients with recurrent pulmonary exacerbationsuntil May 2031
Utah State Higher Education System--University of Utah
Salt Lake City, United States
- Erm(41) Mediated Macrolide Resistance in Mycobacterium abscessusuntil Aug 2028
The 31 most recently started of 391 running projects are listed.
Sources: NIH RePORTER and CORDIS (European Commission, CC BY 4.0), filtered by disease.
About cystic fibrosis
Sources: NHS, MedlinePlus, Journal of Cystic Fibrosis
An inherited condition that makes the body produce thick, sticky mucus, which can affect the lungs and the digestive system. Common signs are a lasting cough with mucus, frequent chest infections and, in children, slow growth. There is no cure yet, but medicines, physiotherapy and diet support can help. A child gets it only when both parents pass on the altered gene, and many people diagnosed today are expected to live well past middle age.
What is it?
Cystic fibrosis (CF) is a rare inherited condition. The body makes thick, sticky mucus that can affect the lungs and the digestive system and makes infections more likely. It mostly affects the lungs, the pancreas, the liver, the gut, the sinuses and the sex organs.
A child gets CF only when both parents pass on an altered gene. Someone who gets the gene from just one parent usually has no symptoms but is a carrier. When two carriers have a child, there is a 1 in 4 chance that the child has CF. If you have CF or are a carrier, you can ask for genetic counselling before having a baby.
The first signs
Most babies are now found through newborn screening.
- a cough that does not go away and brings up mucus;
- wheezing and shortness of breath;
- frequent chest and sinus infections;
- large, greasy poos that are hard to flush, constipation, tummy pain or bloating;
- slow growth in children, or weight loss in adults;
- very salty sweat.
Some people have a milder form that does not show until the teenage years or early adulthood.
How doctors find out
All babies are checked for cystic fibrosis with the newborn blood spot test. If it suggests CF, a sweat test measures the salt in the sweat, which is usually high in CF. Older children and adults have a blood test and then a sweat test. Relatives of someone with CF, and partners of carriers, can have a test to see if they are carriers.
Current treatment
Care from a specialist CF team combines CFTR modulator medicines, airway-clearing medicines and physiotherapy, antibiotics for infections and a high-energy diet, with a lung transplant for some.
Will it get worse?
CF needs care for life and can shorten life. Over time it can lead to lung damage and other problems such as diabetes, liver disease, weak bones and difficulty having children, and many of these can be treated. Thanks to newer treatments many symptoms can be managed, and many people diagnosed today are expected to live well past middle age.
Medicines: what helps, and what to watch for
CFTR modulators are medicines that lessen the effect of the altered gene, so the lungs work better. Other medicines open up the airways or help clear mucus, antibiotics treat infections, and steroids calm swelling in the airways. Devices such as inhalers and specially designed masks can help with breathing and clearing mucus.
Good to know:
- you are cared for by a CF team, usually based at a larger hospital, with specialist doctors and nurses, a physiotherapist and a dietitian;
Exercise and therapy help too
- a physiotherapist can teach you ways to improve your breathing and posture, which helps clear mucus from your lungs;
- staying active also helps clear mucus;
A lung transplant, for some people
If other treatments stop working, some people may in time need a lung transplant. It is not suitable for everyone.
Is there a cure?
Not yet. Treatments have improved greatly in recent years, and gene editing shows promise.
Median survival
Median survival age at birth about 46 years (males) and 41 years (females), UK data 2011–2015
Measured in: People in the UK Cystic Fibrosis Registry, 2011–2015 (10,428 people); survival age counted from birth
The figures behind it
UK Cystic Fibrosis Registry data, 2011–2015 (10,428 people, 602 deaths): median survival age at birth 46 years for males and 41 years for females with two copies of F508del, similar for others diagnosed at birth. If mortality keeps improving at the same rate, the projection is 65 (males) and 56 (females).
Sources
Written in plain words by Frontlight from these pages: